BioSpace News Archive

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis.

Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression Anxiety in Alzheimer’s Disease.

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) today reports fourth quarter and year end 2023 financial results and provides a corporate update.

Agenus Inc. today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024.

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, reported financial results and business highlights for the fourth quarter and year ended December 31, 2023, and provided full-year 2024 financial guidance.

MoonLake Immunotherapeutics announced its financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

ZyVersa Therapeutics, Inc. announces that on February 26, 2024, the company generated approximately $2.7 Million from existing investors’ exercise of previously issued warrants.

Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that its lead development program, Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, has completed Stage 2 enrollment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort of the NAVAL-1 trial.

NANO-X IMAGING LTD and Beilinson Hospital announced their collaboration to conduct a clinical study evaluating the Nanox.ARC 3D imaging system in a clinical outpatient setting at Beilinson Hospital.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 7, 2024, to report its fourth quarter and full year 2023 financial results and provide recent business progress.